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Abstract: Lower urinary tract neoplasia in companion animals is a debilitating and often
life-threatening disease. Tumors of the bladder, urethra, and prostate often occur independently,
although extension of these tumors into adjacent regions of the lower urinary tract is documented
frequently. The most common lower urinary tract tumor in dogs and cats is transitional cell carcinoma
(TCC). In both dogs and cats, TCC affecting the urinary bladder is generally considered to be highly
aggressive with both local and metastatic disease potential, and this disease poses unique treatment
challenges. Whereas much literature exists regarding the TCC disease process, treatment options, and
prognosis in dogs, relatively few studies on feline TCC have been published due to the lower incidence
of TCC in this species. Prostate tumors, most commonly adenocarcinomas, occur less commonly in
dogs and cats but serve an important role as a comparative model for prostate neoplasia in humans.
This article serves as a review of the current information regarding canine and feline lower urinary
tract neoplasia as well as the relevance of these diseases with respect to their human counterparts.
Keywords: neoplasia; urinary; lower urinary tract; bladder; carcinoma; prostate; transitional
cell carcinoma
1. Background
The urinary bladder is the most common site of lower urinary tract neoplasia in both dogs and
cats [1,2]. In dogs, the urinary bladder is also the most common site of neoplasia in the entire urinary
system (including both upper and lower urinary tracts), and in cats, the urinary bladder is the second
most common site of neoplasia in the urinary tract (after renal lymphoma) [1,2]. Urinary bladder
neoplasia comprises approximately 2% of all canine malignancies, and the most prevalent urinary
bladder cancer in dogs is transitional cell carcinoma (TCC) [3–9]. Metastatic urinary bladder tumors
are infrequently reported in dogs, but local extension from urethral or prostatic tumors into the urinary
bladder occurs commonly [5,10]. Bladder neoplasia occurs less frequently in cats, with a reported
incidence of 0.07–0.18% [11]. However, a recent multi-institutional, retrospective study included 118
cats with urinary bladder TCC, and the incidence of this disease in cats may be greater than previously
suspected [12].
Prostate tumors in dogs occur less frequently than urinary bladder tumors with a reported
incidence of 0.2–0.6% [13–17]. The most common type of prostatic neoplasia in dogs is
adenocarcinoma [15]. Although the incidence is low, the spontaneous development of this cancer
in dogs (which is rare in other domestic species) has led to further evaluation of canine prostatic
carcinoma as a comparative model for prostatic carcinoma in humans [15,18,19]. TCC of the prostatic
urethra frequently invades the prostate, such that it can be difficult to determine whether TCC in the
prostate is primarily of prostatic epithelial origin or secondary to invasion from a urethral tumor [18].
Prostatic tumors in cats are very rare, and few published reports of feline prostatic adenocarcinomas
exist [20–22].
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2. Transitional Cell Carcinoma of the Lower Urinary Tract in Dogs
2.1. Neoplastic Behavior and Classification
In general, TCC is an aggressive, highly invasive tumor with a predisposition for a trigonal
location in dogs [3–7]. Most canine lower urinary tract TCCs are reported as high grade, papillary,
infiltrative tumors [7–9]. In a study of 102 dogs with urinary bladder TCC (the majority of which
involved the trigone), TCC also involved the urethra in 56% of dogs and the prostate in 29% of male
dogs [5]. Local disease, with frequent trigonal location and urethral involvement, can result in clinical
signs associated with lower urinary tract disease (dysuria, hematuria, pollakiuria, and stranguria) and
obstruction of the urinary tract [3,8,9]. A guideline for staging of canine bladder neoplasia has been
recommended in accordance with the World Health Organization (WHO) in order to guide therapy
and provide information on prognosis [23]. Importantly, the bladder tumor grade and TNM stage in
accordance with this WHO classification system has been demonstrated to correlate with outcome in
these patients [5,7]. According to this criteria, 78% of dogs that are diagnosed with TCC have been
reported to have T2 stage disease (tumors that invade the bladder wall), and 20% of dogs with TCC
have been reported to have T3 stage disease (tumors that invade adjacent viscera including prostate,
uterus, vagina, and pelvic canal) [8,9]. An updated classification scheme for canine TCC was suggested
in 2006 [24].
Canine TCC has a high rate of metastasis, with lymph node metastasis in 16%, distant metastasis
in 14%, and both nodal and distant metastasis in 10% of dogs at the time of diagnosis [5]. Documented
metastasis at the time of diagnosis has been associated with a worse prognosis in these dogs [3,9]. At the
time of death, distant metastasis has been reported in 49–58% of dogs with TCC [5,8]. Despite the high
incidence of metastatic disease, progression of local disease with subsequent urinary tract obstruction is
the cause of death for many dogs with TCC in which the primary tumor is not adequately controlled [5].
Alternatively, in canine patients with adequate primary tumor control, metastatic disease is seen more
frequently than urinary tract obstruction at the time of death [5]. This finding demonstrates the
importance of both local and systemic treatment in these patients, as the disease is both locally
invasive/aggressive and has a high rate of metastasis. In a study of 102 dogs, the cause of death
(known for 85/102 dogs) was associated with the primary tumor in 61% of dogs, metastatic disease
in 14% of dogs, and non-TCC related problems in 25% of dogs [5]. In a report on 137 dogs with TCC
that had necropsies performed, 67% of dogs had documented metastasis in any location with nodal
metastasis in 42% of dogs, regional (abdominal, pelvic, and/or inguinal lymph nodes) metastasis in
29% of dogs, any distant metastasis in 58% of dogs, pulmonary metastasis in 50% of dogs, and skeletal
metastasis in 11% of dogs [8,9].
2.2. Risk Factors and Clinical Signs
Risk factors for lower urinary tract TCC in dogs include female sex, historical spay or neuter,
breed (particularly Scottish Terriers with a 21-fold increased risk relative to mixed breeds), obesity,
exposure to certain flea control products and lawn chemicals, potential exposure to cyclophosphamides,
and living in an industrial area [2,4,5,8,9,25]. TCC typically affects older dogs, and the mean age at
diagnosis has been reported at 11.05 years [5]. The most common clinical signs associated with TCC
in dogs include stranguria, hematuria, and pollakiuria, though other possible clinical signs include
tenesmus, lethargy, lameness, and weight loss [2,3,5,9]. Duration of clinical signs ranges from weeks to
months prior to diagnosis [3,9].
2.3. Diagnosis
Definitive diagnosis of lower urinary tract TCC is vital to providing appropriate prognostic
information and treatment recommendations [9]. Definitive diagnosis of TCC typically entails
histopathological assessment of tissues obtained via surgery, cystoscopy, or catheter biopsy [3,4,8,26,27].
Transurethral cystoscopic biopsy may be a greater asset in female dogs than male dogs, however, as
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this method has been reported to accurately diagnose disease in 96% of female dogs but only 65%
of male dogs with confirmed lower urinary TCC [28]. Cytology also has a role in diagnosis of TCC,
although urine cytology (i.e., assessing for malignant transitional cells in urine) can result in both false
negative and false positive results and should be interpreted with caution [9]. Though percutaneous
aspirates or biopsies can be adequate means of attaining a diagnosis, these methods may increase the
propensity for TCC to seed within the abdomen or body wall [3,4,9,29–31]. A TCC urine antigen test
has been reported as a sensitive diagnostic test, but false positives are possible [9,32]. A droplet digital
PCR assay to detect a BRAF V595E gene mutation has also been described for dogs with TCC [33,34].
This assay has a reported sensitivity of 85% and specificity of 100% when used on free catch urine
samples of dogs with both urothelial and prostatic carcinoma [33]. Therefore, a positive BRAF mutation
test result can be considered as diagnostic for urothelial (or prostatic) carcinoma in dogs, and this test
serves as a valuable minimally invasive tool for obtaining a diagnosis in these patients.
2.4. Staging
In dogs with confirmed or suspected lower urinary tract TCC, thorough evaluation of systemic
health and staging of the disease should be performed. Evaluation should include physical examination
(including rectal exam), complete blood count, serum biochemistry panel, urinalysis, urine culture,
thoracic radiographs, abdominal ultrasound, and additional lower urinary tract imaging [3,9].
Findings on rectal examination can include urethral and trigonal thickening or mass effect and
sublumbar lymphadenopathy [3,9]. To reduce the risk of neoplastic seeding (though relatively rare),
urine may be obtained via voiding or catheterization rather than cystocentesis [3,9]. Because dogs
with TCC are predisposed to development of secondary urinary tract infections, and because the
clinical signs of lower urinary tract TCC often mimic those of a urinary tract infection, urine culture
is recommended [9,35]. Thoracic and abdominal imaging can be valuable staging tools to assess for
evidence of metastatic disease in the lungs, lymph nodes, liver, and other locations [9]. If lameness is
documented, skeletal radiographs, computed tomography (CT), and/or nuclear scintigraphy may be
indicated to assess for possible bone metastasis [9]. Imaging of the urinary tract is important in order to
determine tumor location, extent, and feasibility of surgical intervention, evaluate for prognostic
information, and obtain baseline measurements to aid in monitoring response to treatment [9].
Imaging modalities for obtaining this information include ultrasound, cystography (which may
include double-contrast cystogram, intravenous urogram, and retrograde urethrocystogram), and
CT [36–39].
2.5. Treatment
Reported treatments for dogs with lower urinary tract TCC include surgery, radiation therapy,
medical therapy (primarily including cyclooxygenase (COX) inhibitors and chemotherapy), and
local intravesical therapy. Potential indications for surgical intervention in dogs with TCC include
acquisition of a biopsy for diagnosis, excision of the tumor, and restoration or maintenance of urine
flow [3,9]. The role of surgical excision in the treatment of dogs with TCC is limited in most cases
due to the typical trigonal location, high frequency of urethral involvement, potential for diffuse
malignant transformation of the urothelium (“field effect”), and commonly documented metastatic
disease at the time of diagnosis [3,5,9]. Techniques for trigonal excision, total/subtotal cystectomy,
and incorporation of grafting materials to reconstruct the urinary bladder have been described in
dogs, but these techniques are rarely used in clinical patients due to a high risk of morbidity and
significant expense [4,5,9,40–45]. In a report on 102 dogs with TCC that underwent partial cystectomy
or cytoreductive (debulking) surgery, complete resection (i.e., tumor free margins on histopathology)
was documented in only 2/102 dogs [5]. In two studies on dogs that underwent partial cystectomy
or cytoreductive surgery, median survival times were reported at 106 days and 125 days [2,46].
One possible reason for poor outcomes in dogs that undergo partial cystectomy or a cytoreductive
procedure for lower urinary tract TCC involves the potential development of post-operative recurrence
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or multifocal/diffuse TCC in the urinary bladder; possible causes for this finding include the “field
effect,” in which the entire bladder surface undergoes malignant transformation, and/or seeding
within the bladder lumen (which may occur secondary to surgical manipulation) [3,47]. An important
consideration in dogs that undergo surgical procedures related to lower urinary tract TCC is the
potential for peritoneal seeding. One report has documented seeding of TCC to the peritoneal
wall in 24/544 dogs, and dogs that underwent cystotomy/cystectomy procedures had an increased
incidence of this seeding phenomenon (18/177, 10.2%) compared to dogs that did not undergo
cystotomy/cystectomy procedures (6/367, 1.6%) [9,31]. In that report, dogs that were diagnosed
with spread of TCC to the peritoneal wall had a poor prognosis with a median survival time of
57 days [31]. These findings emphasize the importance of careful techniques (including both surgical
and non-surgical) in an effort to minimize seeding of this neoplasm.
Due to the historically poor outcomes, the role of surgery in management of dogs with lower
urinary tract TCC has become largely palliative in nature with procedures aimed at maintenance
or restoration of urinary tract patency without directly altering tumor progression. In particular,
placement of urethral and ureteral stents has been described for this purpose, and minimally
invasive techniques for these procedures have become available [48–51]. Urethral stents are now
more commonly placed than cystostomy tubes to maintain urinary flow in the event of urethral
obstruction in dogs due to a reduction in complications and compliance issues with stents [9,49–51].
In two studies, urethral stents were successful in relieving urethral obstruction in 58/61 dogs [49,50].
Possible complications following urethral stent placement procedures include urinary incontinence,
stent migration, re-obstruction with continued tumor growth, and increased risk of urinary tract
infections [9,49,50]. Median survival time of 78 days has been reported after stent placement,
although this number increased to 251 days when adjuvant treatment was also performed (i.e., stent
placement performed after nonsteroidal anti-inflammatory drug (NSAID) administration and prior to
chemotherapy); moreover, the majority of owners reported satisfaction with the outcome following
stent placement [49,50]. Other minimally invasive interventional approaches that have been described
to debulk urethral tumors in dogs, and thereby maintain patency of the urethra, include cystoscopic
transurethral resection (via electrocautery) and cystoscopic transurethral near-infrared diode laser
ablation [52,53]. Transurethral resection of TCC in dogs is somewhat limited due to the invasive nature
of tumor into the wall of the lower urinary tract (rather than more superficial, intraluminal forms that
can be seen in humans with this disease) [9]. One reported risk of laser ablation is perforation of the
urinary tract, and further evaluation of the effect of cystoscopic laser ablation on outcomes in dogs
with TCC is needed [9,53].
Radiation therapy has been performed infrequently for treatment of TCC in dogs. In one report on
intra-operative radiation therapy (i.e., radiation following partial excision of the tumor with the surgical
site exposed) in 11 dogs with urinary bladder TCC, median post-treatment survival time was 15 months
and TCC recurrence was documented in 6/11 dogs [54]. Side effects associated with radiation therapy
in this study included pollakiuria, urinary incontinence, cystitis, stranguria, and hydronephrosis, and
4/11 dogs were euthanized secondary to such adverse events [54]. Another pilot study documented
the use of palliative external beam radiation therapy in conjunction with mitoxantrone and piroxicam
administration in 10 dogs [55]. Clinical improvement and stable disease was reported in 7/10 dogs and
the median survival time was 240 days; minimal side effects associated with radiation therapy were
reported in this study [55]. More recent studies have demonstrated improvement in radiation therapy
protocols that enable more accurate treatment of the tumor site and reduced irradiation of normal
tissues [56,57]. Additional studies are needed to further investigate the role of radiation therapy as
well as optimal protocols for its use in the treatment of canine lower urinary tract TCC.
In dogs with TCC, systemic medical therapies including chemotherapy agents and COX inhibitors
(NSAIDs) are considered to be mainstay treatments [3,8,9]. Multiple chemotherapeutic protocols and
drugs have been studied (including cisplatin, carboplatin, mitoxantrone, doxorubicin, vinblastine,
and gemcitabine), and in general canine TCC is considered relatively resistant to chemotherapy [3–5].
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Although long-term outcome data is limited, evidence suggests a potential benefit of chemotherapy
administration via an intraarterial route [58]. As compared to canine patients that received intravenous
carboplatin for treatment of lower urinary tract carcinoma, patients that received intraarterial
carboplatin were more likely to have a tumor response and experienced greater decreases in tumor
size [58]. A clinical trial on the use of piroxicam in 76 dogs with TCC demonstrated complete remission
in 2.6% of dogs, partial remission in 18.4% of dogs, stable disease in 59.2% of dogs, and progressive
disease in 19.7% of dogs; the median survival time of these dogs was 244 days [59]. Prior to this
data, the response rate to any single-agent medical therapy protocol (chemotherapeutic drug or
NSAID) was less than 25% with a survival time of approximately 6 months or less [1,5]. Based on this
study, however, piroxicam may be a reasonable single-agent approach for treatment of lower urinary
tract TCC in dogs [9]. Another study demonstrated a potential role for firocoxib as a single-agent
therapeutic approach for dogs with TCC; in this study, firocoxib induced partial remission in 20% and
stable disease in 30% of dogs with urinary bladder TCC [60]. However, multimodal medical therapy
has resulted in an improved survival time in dogs with TCC. For instance, dogs treated with both
mitoxantrone and piroxicam had a median survival time of 291 days [61]. The currently accepted and
recommended approach to medical therapy in dogs with lower urinary tract TCC involves sequential
administration of multiple drugs (chemotherapy agents and NSAIDs) over the course of the disease [3].
The approach outlined by the Purdue University Veterinary Teaching Hospital involves initiation of a
medical treatment protocol with monitoring of treatment response every 4-8 weeks and subsequent
changes in the protocol based on tumor response and treatment tolerability [3]. Although medical
therapy is not considered curative in dogs with lower urinary tract TCC, by following this protocol,
TCC growth has been reportedly controlled in approximately 75% of dogs and median survival times
have reached 1 year or greater in these canine patients [3,9].
Intravesical therapy has also been reported in dogs with lower urinary tract TCC. A clinical trial
documented the administration of intravesical mitomycin C (MMC) in dogs with TCC [62]. Although
partial remission and stable disease occurred in 5/13 and 7/13 dogs, respectively, severe systemic
side effects (myelosuppression and gastrointestinal signs) occurred in 2/13 dogs [62]. Due to the
potential for systemic absorption and adverse effects, intravesical MMC is not recommended at this
time [9,62]. Other treatment modalities for canine TCC are emerging, and these include metronomic
chemotherapy, folate-targeted therapy, and demethylating agents [9]. Additional studies are needed to
further evaluate their role in the treatment of lower urinary tract TCC in dogs.
2.6. Relevance to Human Lower Urinary Tract Transitional Cell Carcinoma
Transitional cell carcinoma of the lower urinary tract in dogs closely resembles high-grade
invasive TCC in humans with similar cellular and molecular characteristics, biological behavior, and
response to treatment [4,5,8]. Studies on naturally occurring TCC in dogs add to the data that has
been acquired in studies on experimentally induced TCC in rodents; the findings obtained from these
studies may initiate improvement in the early diagnosis, treatment, and outcomes in humans and dogs
with TCC [8]. For instance, studies that investigate the effect of COX inhibitors, targeted therapies,
epigenetic based therapy, and metronomic chemotherapy on canine patients with TCC have shown
translational promise for studies in human medicine [8]. One aspect of lower urinary tract TCC that
appears to be relatively unique to dogs is that of the high incidence of BRAF genetic mutations, as
BRAF mutations are a rarely reported feature of TCC in humans [33,63]. However, this information
may serve to enhance the knowledge-base and prompt additional studies on the small subset of human
patients with BRAF mutation-positive TCC, or alternatively, can be translated into research on other
tumor types in humans that are more commonly associated with BRAF mutations, such as malignant
melanoma [63].
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3. Transitional Cell Carcinoma of the Lower Urinary Tract in Cats
Because the incidence of lower urinary tract TCC is much lower (0.07-0.18%) in cats relative to
dogs, very few feline TCC studies have been published [11]. Until recently, the largest retrospective
study on feline TCC documented 20 cases of urinary bladder TCC in cats [64]. However, a recent
multi-institutional, retrospective study reported on 118 cats with lower urinary tract TCC [12].
Treatments performed on these cats included partial cystectomy, NSAIDs, chemotherapy, radiation
therapy, and urethral/ureteral stent placement [12]. Tumor location was significantly more variable in
these cats than in dogs with TCC, and a trigonal tumor location was reported in 27.1% of the cats [12].
At study completion, metastatic disease was documented in 21.2% of all cats [12]. Primary tumor local
progression or recurrence occurred in 55.6% of cats (with recurrence following cystectomy reported in
21.2% of cats post-operatively) [12]. The median survival time for all cats was 155 days, and treatment
was significantly associated with survival [12]. The median survival times for untreated cats, cats
treated without cystectomy, and cats treated with cystectomy were 46 days, 176 days, and 294 days,
respectively [12]. Cats with trigonal disease and a presenting complaint of lethargy were significantly
less likely to receive treatment [12]. On multivariable analysis, surgical excision (cystectomy) and
NSAID administration were significantly associated with longer survival in cats with lower urinary
tract TCC [12].
4. Prostatic Carcinoma in Dogs
4.1. Neoplastic Behavior and Classification
The majority of prostate tumors in dogs are carcinomas, and of those, most are
adenocarcinomas [18]. Prostate carcinoma in dogs generally arise from urothelial or duct cells rather
than acinar cells, and most canine prostatic tumors are androgen receptor-negative and, subsequently,
androgen independent [18,65–71]. Moreover, cyclooxygenase-2 (COX-2) expression, though not seen
in normal prostate cells, has been detected in 75% of canine prostate carcinoma cells [72]. Historical
subclassification of prostatic carcinomas in dogs has been based on differentiation of these tumor cells
and include glandular, urothelial, squamoid, and sarcomatoid forms [15]. However, a more recently
developed classification scheme is based on growth patterns and includes papillary, cribriform, solid,
small acinar/ductal, signet ring, and mucinous tumor types [73]. Regardless of the classification
method, prostate carcinoma in dogs appears to be a uniformly aggressive neoplasm. Local invasion
and metastasis are common with canine prostatic carcinoma [18]. One study on 76 dogs with prostate
carcinoma documented metastatic disease in 80% of the dogs at necropsy [15]. The most common sites
of metastasis included lungs and lymph nodes [15]. Prostatic carcinoma in dogs also has a predilection
for bone, and skeletal metastasis has been reported in 22–42% of dogs with prostate carcinoma; the
most common sites of skeletal metastasis include the lumbar vertebrae and pelvis [15,18,69,74,75].
As with human prostatic carcinoma, this propensity for skeletal metastasis may be associated with both
osteolytic and osteoblastic potential of these prostate carcinoma cells [76]. Some evidence suggests
that younger dogs with prostate carcinoma have an increased risk of metastasis, although the effect of
castration status on this finding is unclear [15,18,77]. Although metastasis is a common component of
this disease process, sequellae of the locally aggressive nature of prostate carcinomas, including pain,
severe dyschezia, and urinary obstruction, are often the cause of death/euthanasia in these dogs [78].
4.2. Risk Factors and Clinical Signs
Prostatic tumors are most commonly seen in older dogs with a mean age of 10 years at
diagnosis [14,15]. Although prostate carcinomas have been detected in both intact and castrated
male dogs, an increased risk of this disease has been demonstrated in castrated male dogs with an odds
ratio of approximately 2.3:4.3 [13,65,68,79,80]. Importantly, this finding is in contrast to the increased
risk of development of bacterial prostatitis and benign prostatic hyperplasia in intact male dogs relative
to castrated male dogs [81]. Moreover, castrated male dogs may be predisposed to more aggressive
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prostate tumors with a higher risk of metastasis compared to intact males [18,79]. Benign prostatic
hyperplasia has not been documented as a risk factor for development of prostate carcinoma in
dogs [82]. Several dog breeds have been reported to have an increased risk of developing prostate
carcinoma; those include the Bouvier des Flandres, Doberman Pinscher, Shetland Sheepdog, Scottish
Terrier (even when accounting for the increased risk of TCC in this breed), Beagle, Miniature Poodle,
German Shorthaired Pointer, Airedale Terrier, and Norwegian Elkhound [68,80]. Common clinical
signs in dogs with prostate carcinoma include dysuria, hematuria, stranguria, dyschezia, tenesmus,
and flattened/ribbon-like stools (secondary to rectal compression from the prostatic mass and/or
metastatic lymph nodes) [15,75,78,79,83]. Patients can present with urinary obstruction secondary
to prostatic compression of or tumor extension into the urethra [18]. Other presenting complaints
include pain, lameness or gait abnormalities (secondary to tumor invasion of lumbar vertebrae and/or
nerve roots), constipation, and non-specific signs of illness such as lethargy, inappetance, and weight
loss [18].
4.3. Diagnosis
Definitive diagnosis of prostate carcinoma is obtained via biopsy and/or cytology [18,78,83,84].
Means of obtaining samples for cytology include traumatic catheterization, prostatic massage, prostatic
wash, ejaculation, ultrasound-guided fine needle aspiration, and impression smears from biopsy
samples [18]. Methods for obtaining samples for biopsy include percutaneous, perineal/transrectal,
and surgical [18]. Cytology or histopathology can also be performed on suspected metastatic lesions
(such as lymph nodes) to aid in diagnosis and staging of this disease in dogs [18]. Similar to TCC of the
urinary bladder, there is a risk of seeding prostate carcinoma cells along needle tracts during aspiration
or biopsy, such that caution should be taken when performing these diagnostic tests [18,29,85].
4.4. Staging
Thorough systemic evaluation and staging should be performed on dogs with prostate carcinoma.
Complete systemic evaluation includes physical and rectal examination, complete blood count, serum
biochemistry panel, urinalysis, and urine culture. An enlarged, painful, asymmetric prostate is the
most common finding on physical and rectal examination, and rectal examination can also reveal
enlarged sublumbar lymph nodes [18,85]. Other possible findings on physical examination include
musculoskeletal pain and/or lameness and a palpable abdominal mass [85]. Findings on complete
blood count and serum biochemistry profile can include anemia, leukocytosis (particularly if secondary
infection is present), and hypercalcemia and/or elevated alkaline phosphatase (particularly if skeletal
metastasis is present) [18,78]. Urinalysis changes are typically non-specific, though signs consistent
with urinary inflammation or secondary urinary tract infection can be detected [18,78]. Thoracic and
abdominal imaging should be performed via thoracic radiographs and abdominal ultrasound and/or
radiographs. Imaging may also include skeletal survey radiographs and CT or MRI scans. Thoracic
radiographs can reveal pulmonary and/or skeletal metastasis [15,74,79]. Abdominal radiographs
can reveal prostatomegaly, prostate mineralization, sublumbar or retroperitoneal lymphadenopathy,
and periosteal reactions of the vertebrae, pelvis, or femur [18,75,79,86,87]. Abdominal ultrasound can
reveal heterogeneous changes of the prostate gland, disruption of the prostatic capsule, sublumbar
lymphadenopathy, and evidence of other visceral metastasis [15,79,85–87]. Transrectal ultrasound
is another recently described modality for obtaining further information about the prostate and
locoregional lymph nodes [88]. Although prostatic mineralization in dogs with neoplasia has not been
associated with prognosis, the finding of mineralization on imaging can help to guide clinical diagnosis.
Mineralization of a prostatic mass is highly sensitive (84%) and specific (100%) for neoplasia in castrated
dogs; alternatively, in intact dogs, prostatic mineralization (regardless of the extent of mineralization)
may occur with neoplasia, paraprostatic cysts, benign prostatic hyperplasia, or prostatitis [86,89,90].
Survey bone radiographs and/or bone scintigraphy can be performed to help assess for skeletal
metastases in patients in which a clinical suspicion for this phenomenon is present [18,85,91]. Skeletal
Vet. Sci. 2018, 5, 96 8 of 17
metastases in dogs with prostate carcinoma can consist of osteoblastic, osteolytic, or mixed osteoblastic
and osteolytic lesions; when these metastases occur in long bones, they can affect the diaphysis or
metaphysis [74,82,92].
4.5. Treatment
Multiple treatment modalities have been reported in dogs with prostatic carcinoma. In general,
however, the prognosis for these dogs is guarded due to the aggressive nature of this disease (both
locally and systemically) and relatively poor response of the disease to conventional treatments [78].
The reported median survival time for dogs without treatment is typically less than 30 days, and
many dogs are euthanized at the time of diagnosis [15,93]. A standard-of-care consensus therapy
for dogs with prostatic tumors does not currently exist (although administration of NSAIDs is often
recommended at a minimum), and therapy has historically largely been considered palliative [18,82].
Although androgen deprivation therapy is a common treatment modality in men with prostate
carcinoma, hormonal therapy is unlikely to be effective and is not indicated in dogs with prostate
carcinoma due to the typically insignificant role of androgens in canine prostate cancer [15,78,80,82].
Treatment strategies that have been reported in dogs with prostate carcinoma include palliative
therapy for maintenance of urethral patency, NSAID administration, chemotherapy, surgery, radiation
therapy, palliative therapy for alleviation of pain associated with skeletal metastasis, and minimally
invasive interventional procedures including intraarterial chemotherapy, transarterial embolization,
and thermal ablation.
In patients with partial or complete urethral obstruction secondary to prostate carcinoma,
management strategies may include urethral stent placement, prazosin administration, and cystostomy
tube placement [78]. As previously discussed, urethral stents can be placed in a minimally invasive
fashion with successful relief of urethral obstruction, and this technique has largely replaced the use of
cystostomy tubes in dogs [51,94]. One study on seven dogs with prostatic carcinoma and secondary
urinary tract obstruction (partial or complete) demonstrated that administration of prazosin (an alpha-1
antagonist) can be used to temporarily alleviate dysuria and obstruction in these patients [95].
Canine prostatic carcinoma frequently expresses COX-1 and COX-2, and the administration of
NSAIDs has resulted in an improved outcome in dogs with prostate tumors [93]. One study on dogs
with prostate carcinoma showed that dogs treated with piroxicam or carprofen survived significantly
longer (6.9 months) than dogs that were not treated with NSAIDs (0.7 months) [93]. Alternatively, the
role of chemotherapy in dogs with prostate carcinoma is unclear, and there exists little evidence to
date to support a recommendation of conventional chemotherapy agents in the treatment of canine
prostatic carcinoma [18,78]. One study demonstrated effectiveness of nanoparticulate paclitaxel when
used in vitro on canine prostate cancer cells, though further studies are needed to determine the
effectiveness of this agent in clinical patients [96].
Surgery for canine prostatic carcinoma includes total and partial prostatectomy techniques.
Although total prostatectomy can relieve signs associated with urethral obstruction, significant
complications (including urinary incontinence) and progression of local and systemic disease have
been reported post-operatively without a clear survival benefit in these patients [18,52,82,85,97,98].
However, in a recent study on 25 dogs with prostate neoplasia, total prostatectomy, when combined
with adjunctive therapies such as NSAIDs and chemotherapy, resulted in a median survival time of 231
days [99]. Major post-operative complications that required a subsequent surgical procedure occurred
in 4/25 dogs that underwent total prostatectomy [99]. Permanent post-operative urinary incontinence
was present in 35% (8/23) of dogs with follow-up information after total prostatectomy [99]. Subtotal
intracapsular prostatectomy has also been described as an alternative to total prostatectomy, and
fewer adverse effects have generally been reported secondary to this procedure compared to total
prostatectomy [100]. One prospective study on 21 dogs demonstrated an improved median survival
time in dogs that underwent subtotal intracapsular prostatectomy (130 days) relative to dogs that
underwent total prostatectomy (17 days) [100]. However, 2/11 dogs that received subtotal intracapsular
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prostatectomy and 3/10 dogs that received total prostectomy experienced severe post-operative
complications and were euthanized within 2 weeks post-operatively [100]. Partial prostatectomy via
a neodymium:yttrium-aluminium-garnet (Nd:YAG) laser filleting technique has also been reported
in an effort to allow preservation of the prostatic urethra and subsequently reduce the incidence and
severity of post-operative urinary incontinence in dogs [18,101,102]. However, a risk of significant
post-operative complications still exists with this technique, and one study reported that 3/8 dogs
with prostate carcinoma that underwent this treatment died from complications within 16 days of the
procedure [102]. When evaluating the use of photodynamic therapy with 5-aminolevulinic acid in
combination with partial prostatectomy via Nd:YAG laser, outcomes were relatively poor with rapid
progression of disease and a median survival time of 41 days [102]. Transurethral prostate resection
with an electrocautery cutting loop has been performed on three dogs (that also received adjunctive
treatment) with prostate carcinoma via cystotomy and antegrade cystoscopy [52]. Improvement
in clinical signs was noted in all three dogs, but survival times were short (32, 74, and 264 days
post-operatively) and reported complications included tumor seeding, urethral perforation, and
urinary tract infection [52]. Overall, evidence to date demonstrates a potential role for surgery in
palliation of clinical signs with canine prostatic carcinoma, but surgery has typically not been shown
to have a significant survival benefit in these patients and can result in substantial post-operative
complications [18,82]. Further studies are needed to help guide surgical indications and modalities in
dogs with prostate carcinoma.
Radiation therapy has also been performed for treatment of dogs with prostate carcinoma.
One study documented the use of intra-operative orthovoltage radiation therapy on dogs with
prostate carcinoma and revealed a median survival time of 114 days [103]. A more recent study
on intensity-modulated and image-guided radiation therapy on dogs with genitourinary carcinomas
showed potential clinical benefit in 90% of dogs and median survival time of 654 days for all dogs
in the study, and dogs with prostate carcinoma had a median event-free survival time of 317 days
(where events included disease progression, late radiation-associated toxicosis, death, and loss to
follow-up) [57]. Radiation therapy may also have a role in palliation of clinical signs associated
with the prostate tumor and skeletal metastases [18,78,82]. Other reported treatment modalities for
palliation in dogs with osseous metastasis include the use of bisphosphonates (osteoclast inhibitors)
and samarium-153-ethylenediamine-tetramethylene phosphonate [104–106].
More recently, novel techniques for treatment of prostate carcinoma in dogs, including
embolization and ablation, have been described. One preliminary study on the use of transarterial
prostatic embolization in dogs with benign prostatic hypertrophy showed significant decrease in
prostate size in 4/7 dogs and increase in prostate size characterized by a large cavity within the
prostate in 3/7 dogs; complications were not encountered in any of the dogs [107]. An ongoing study
at the authors’ institution has documented that all dogs with prostate tumors that have undergone
transarterial prostate embolization have had positive outcomes post-procedure with a decrease in
tumor size, improvement in clinical signs, and lack of major complications [108]. Previous studies have
documented feasibility of percutaneous ultrasound-guided radiofrequency electrocautery ablation,
high-intensity focused ultrasound for subtotal ablation, transurethral radiofrequency ablation with a
saline electrode, and irreversible electroporation in canine prostate tissue; one report has documented
the use of radiofrequency ablation for treatment of prostate carcinoma in a dog [109–113]. Further
studies are needed to determine the clinical applicability and outcome of ablation in dogs with
prostate carcinoma.
4.6. Relevance to Human Prostatic Carcinoma
Although in general, canine prostatic carcinoma is more aggressive and less differentiated than
prostatic carcinoma in humans, canine prostatic carcinoma is an ideal animal model for cases of poorly
differentiated, androgen-refractory (hormone non-responsive) prostate carcinoma in men [71,82].
Moreover, despite the low incidence of prostate carcinoma in dogs, the dog is one of the few
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known domestic species that develop spontaneous prostate neoplasia, and as such, dogs represent
an important comparative model to enhance understanding of this disease in people [18]. Data from
human prostate carcinoma studies can also be used to advance the management of prostate carcinoma
in dogs. For instance, a modified version of the Gleason grading scheme (an important tool for
prognostic information regarding prostate cancer in men) has recently been used on canine prostate
carcinomas with correlation between high scores and more aggressive neoplastic behavior [114].
5. Prostatic Carcinoma in Cats
Prostate neoplasia is considered very rare in cats and literature is subsequently lacking. Several
case reports exist, with the majority of reported feline prostate tumors being adenocarcinomas in older
castrated male cats [20–22,115–117]. Because of the limited data, no standard-of-care treatment or
prognostic information exists in cats with prostate carcinoma [18]. Metastasis is commonly reported
in the few cases of cats with prostate carcinoma, and reported sites of metastasis include lungs,
lymph nodes, and pancreas. [20–22,115–117]. Most of the reported cats did not survive beyond
3 months of diagnosis of prostate carcinoma [20–22,115–117]. However, one case report documented
long-term survival with no evidence of local or metastatic disease two years post-operatively in a cat
with low-grade prostatic sarcomatoid carcinoma that underwent prostatectomy; another case report
documented a 10 month survival time in a cat that underwent prostatectomy and chemotherapy
(doxorubicin and cyclophosphamide) for treatment of prostate carcinoma. [21,22]. Further studies are
needed to gain more information on prostatic carcinoma in cats and guide treatment recommendations.
6. Miscellaneous Lower Urinary Tract Tumors
Other less common types of bladder neoplasia in dogs include squamous cell carcinoma,
adenocarcinoma, undifferentiated carcinoma, rhabdomyosarcoma, hemangiosarcoma, fibroma, and
other mesenchymal neoplasms [7,118–122]. Primary extranodal lymphoma of the urinary bladder has
also rarely been reported in dogs and needs to be differentiated from multicentric lymphoma with
involvement of the urinary bladder [119]. Polypoid cystitis is another rare urinary bladder disease that
has been documented in dogs and is characterized by inflammation, epithelial proliferation, and the
occurrence of polypoid masses without histopathological evidence of neoplasia; this condition is often
associated with urinary tract infections [123].
Aside from carcinoma, other reported canine prostatic tumor types include TCC, squamous
cell carcinoma, undifferentiated carcinoma, leiomyosarcoma, leiomyoma, hemangiosarcoma, and
lymphoma [79,124–127]. Benign tumors of the prostate are rare and much less common than malignant
prostatic tumors [18]. Transitional cell carcinoma and squamous cell carcinoma comprise the majority
of urethral tumors in dogs, and urethral smooth muscle tumors have been reported uncommonly [3].
In addition to carcinomas, benign and malignant mesenchymal tumors and lymphoma have also
been reported rarely in the urinary bladder of cats [1]. One study reported on the histopathological
diagnosis of 20 urinary bladder neoplasms in cats, and findings included angioma, intravenous
leiomyoma, adenocarcinoma, squamous cell carcinoma, TCC, leiomyosarcoma, hemangiosarcoma,
lymphoma, and embryonal rhabdomyosarcoma; a distinguishing feature of all squamous cell
carcinomas and most sarcomas in these cats was their endophytic nature, as opposed to the exophytic
nature of all adenocarcinomas and most TCC in these cats [128].
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